Compared to TAA, neoantigens present a more appealing target for targeted immunotherapy development due to their higher immunogenicity that is enhanced because of increasing difference between the mutated and normal peptide sequence, strong individual tumor specificity, higher affinity towards MHC, and reduced risk of autoimmunity as they are recognized as foreign antigens and not affected by central immunological tolerance (168). Here, HLA-C is linked to neoplasm.